ASX · LV1.AX
Live Verdure Ltd
A$0.92A$0.00 (0.0%)
Live Verdure Ltd’s quoted price sits in the upper half of its reported 52-week range, 13.68% below the high.
Loading market information…
ASX · NUZ.AX · AUD
Stock price, earnings
Quote as of Oct 27, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Neurizon Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 31.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Neurizon Therapeutics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.92A$0.00 (0.0%)
Live Verdure Ltd’s quoted price sits in the upper half of its reported 52-week range, 13.68% below the high.
A$0.06-A$0.00 (-4.92%)
Antisense Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 47.27% below the high.
A$0.03A$0.00 (0.0%)
Respiri Limited’s quoted price sits in the lower half of its reported 52-week range, 67.0% below the high.
A$0.02+A$0.00 (+7.14%)
Living Cell Technologies Limited’s quoted price sits in the upper half of its reported 52-week range, 16.67% below the high.
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
A$6.60A$0.00 (0.0%)
Medlab Clinical Limited: Healthcare · Biotechnology.
A$0.01-A$0.00 (-10.0%)
Bionomics Limited’s quoted price sits in the lower half of its reported 52-week range, 87.84% below the high.
A$0.01+A$0.00 (+33.33%)
Regeneus Ltd’s quoted price sits in the upper half of its reported 52-week range, 40.0% below the high.
